Stryker Q1 2026 sales rise 2.6%, EPS mixed; maintains full-year growth outlook

Stryker reported a 2.6% increase in net sales to $6.0 billion for Q1 2026, driven by organic growth of 2.4%. Reported EPS rose 14.2% to $1.93, while adjusted EPS fell 8.5% to $2.60, reflecting some cost pressures. The company reorganized its orthopaedics segment to enhance innovation and customer experience. Stryker reaffirmed its 2026 guidance, expecting 8.0%-9.5% organic sales growth and adjusted EPS between $14.90 and $15.10, signaling confidence in its business momentum despite recent challenges.